GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Net Income

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Net Income : $-928.8 Mil (TTM As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Biohaven Pharmaceutical Holding Co's Net Income for the three months ended in Jun. 2022 was $-441.4 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2022 was $-928.8 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Biohaven Pharmaceutical Holding Co's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was $-6.21.


Biohaven Pharmaceutical Holding Co Net Income Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Net Income Chart

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Income
Get a 7-Day Free Trial -127.19 -240.92 -528.81 -766.80 -846.59

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -210.62 -171.82 -199.18 -116.40 -441.39

Biohaven Pharmaceutical Holding Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Biohaven Pharmaceutical Holding Co's Net Income for the fiscal year that ended in Dec. 2021 is calculated as

Net Income(A: Dec. 2021 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-843.323+-5.073+0+1.8099999999999
=-846.6

Biohaven Pharmaceutical Holding Co's Net Income for the quarter that ended in Jun. 2022 is calculated as

Net Income(Q: Jun. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-441.801+-0.084+0+0.49799999999999
=-441.4

Net Income for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-928.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Biohaven Pharmaceutical Holding Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Biohaven Pharmaceutical Holding Co Net Income Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director, 10 percent owner 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile officer: VP of Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman officer: Chief Medical Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Headlines

From GuruFocus